共 157 条
[1]
Piepoli MF(2016)2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J. 37 2315-2381
[2]
Hoes AW(2017)2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways J Am Coll Cardiol. 70 1785-1822
[3]
Agewall S(2018)2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Kardiol Pol. 76 229-313
[4]
Albus C(2017)AACE/ACE comprehensive type 2 diabetes management algorithm 2017 Endocr Pract. 41 S1-S159
[5]
Brotons C(2018)Standards of medical care in diabetes: 2018 Diabetes Care. 39 1131-1143
[6]
Catapano AL(2018)2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia Eur Heart J. 223 750-757
[7]
Lloyd-Jones DM(2016)Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials Int J Cardiol. 9 758-769
[8]
Morris PB(2015)Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial J Clin Lipidol. 176 55-61
[9]
Ballantyne CM(2014)Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial Int J Cardiol. 254 254-262
[10]
Birtcher KK(2016)A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I Atherosclerosis. 37 3588-3595